Applied DNA, Evvivax Initiate Phase I Trial of LinearDNA™ COVID Vax for Cats

 - Vaccine Candidate Previously Demonstrated Antibodies and T-cell Response in Mouse Models -

- Clinical Trial to Serve as Initial Validation of LinearDNA Platform in Large Mammals with Potential Advantages in Manufacturing, Storage, and Distribution over Other Vaccines -

https://www.biospace.com/article/releases/applied-dna-and-evvivax-initiate-phase-i-of-clinical-trial-to-evaluate-lineardna-covid-19-vaccine-candidate-for-feline-veterinary-market/